You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201461 - 201470 of 207712 results
  1. IGF::OT::IGF A Multiparticulate Dispersive Tablet for Pediatric Anti-TB

    SBC: Aucta Pharmaceuticals, LLC            Topic: NIAID

    To support the development of pediatric oral formulations for the anti-TB drugs isoniazid and streptomycin through various chemical processes. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Radix BioSolutions, Ltd.

    SBC: RADIX BIOSOLUTIONS, LTD            Topic: NIAID

    To establish a technology-based platform for simultaneous and sensitive detection of Antibiotic Associated Diarrhea (AAD). This system will be a sensitive quantitative multiplex diagnostic assay consisting of antibodies specific for Clostridium difficile (C. difficile) and non-C. difficile ADD. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Wave 80 Biosciences, Inc.

    SBC: WAVE 80 BIOSCIENCES, INC.            Topic: NIAID

    To support a feasibility study using a bi-partite assay cartridge as a multiplex diagnostic platform for the ultrasensitive detection and quantitation of unamplified nucleic acid targets of influenza A. This innovative system is designed to be compact, fast, and fully automated. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

    SBC: COLBY PHARMACEUTICAL COMPANY            Topic: NCI

    Oral mucositis is a major complication of radiotherapy for the treatment of head and neck cancer and a major dose-limiting side effect. Our work has shown that intra-esophageal administration of plasmidlliposomes containing the transgene expressing humansuperoxide dismutase 2 (SOD2) (JVRSOD) protects the esophagus from radiation-induced esophagitis (a form of mucositis) in mice. The overall pu ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

    SBC: TERAPIO            Topic: NCI

    Oral mucositis (OM) is a common side effect in oncology patients receiving radiation treatment. Mucosal breakdown causes pain which leads to increased use of narcotic analgesics and restriction of food intake. OM often progresses to septicemia, increasinghospital stays and costs, and ultimately discontinuation of radiotherapy. This impacts overall effectiveness of cancer therapy so development of ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    SBC: ASURAGEN, INC.            Topic: NCI

    Asuragen is developing a sensitive, accurate, and reliable test (BCR-ABL1 RT-qPCR Test), for quantification of BCR-ABL1 fusion transcripts to monitor residual disease in patients with chronic myeloid leukemia (CML). Molecular testing for the presence and relative amount of the BCR-ABL1 translocation marker is important for risk stratification and for detecting a loss of response or suboptimal resp ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

    SBC: Omm Scientific, Inc            Topic: NCI

    Radiation insensitive tumors that become radiation resistant are often also invasive, metastatic, and responsible for most cancer deaths. Here, the long term objective is to complete clinical evaluation of an inhibitor of a new target (V-ATPase) that sensitizes tumors but not healthy tissues to radiation and inhibits multiple aspects of tumor metabolism and therapeutic resistance. Development o ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

    SBC: SUVICA INC            Topic: NCI

    The long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HN ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES

    SBC: AVANTGEN INC            Topic: NCI

    Recombinant rabbit monoclonal antibodies as affinity captures for peptides PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC 314: DEVELOPMENT OF HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMOR MICRO

    SBC: HemoShear Therapeutics, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government